In recent years, haematologic treatment has undergone significant progress associated with the introduction of new drug technologies characterised by significant efficacy expressed by a deep response. At the same time the need for conducting and standardising MRD (minimal residual disease) evaluation, which can be used as an indicator for treatment discontinuation, is being debated. The aim of this paper is to indicate the significance of MRD in the assessment of treating CLL (chronic lymphocytic leukaemia) and discussing FTD (fixed time duration) treatment from a clinical and systemic perspective. Current evidence confirms that a negative end-of-treatment MRD status is a strong predictive factor for PFS (progression-free survival) and OS (overall survival) regardless of the type of first-line treatment used and the risk factors. Some new technologies used in CLL treatment (such as venetoclax) are characterised by very high efficacy and can lead to obtaining a deep response, and thus the possibility of using the treatment for a FTD. Obtaining MRD(-) means reducing the number of cancer cells, which decreases the risk of clonal resistance, and thus gives the patients a better prognosis. Administration of the most effective therapy at disease onset is particularly important in CLL treatment. It is underlined that the adopted therapeutic regimen can impact subsequent treatment lines. The greatest benefits of using highly efficacious therapies are reported in first-line treatment, which increases the chances of longer PFS and helps delay the use of subsequent treatment regimens. FTD therapies constitute a beneficial (clinical and systemic) perspective of CLL treatment.

Mariusz Kordecki

Monika Borowiack

Katarzyna Klaś

Journal of Health Policy & Outcomes Research

Journal of Health Policy and Outcomes Research

https://www.jhpor.com/article/2246-the-role-of-minimal-residual-disease-mrd-and-fixed-time-duration-ftd-on-the-example-of-venetoclax-in-chronic-lymphocytic-leukemia-cll---clinical-and-systemic-perspective#

https://www.jhpor.com/article/2246-the-role-of-minimal-residual-disease-mrd-and-fixed-time-duration-ftd-on-the-example-of-venetoclax-in-chronic-lymphocytic-leukemia-cll---clinical-and-systemic-perspective#

ivySCI AI Smartly Parses PDF, Answers Researchers' Questions, and Helps You Understand Papers in Seconds

Journal Info